Sundar Jagannath MD

PubMed

• 3 citations
  Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.
  Sundar Jagannath, Thomas G Martin, Yi Lin, Adam D Cohen, Noopur Raje
  Journal of Clinical Oncology. 2025-09-01
• Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy.
  Adolfo Aleman, Oliver Van Oekelen, David T Melnekoff, Leah Grossman, Tarek H Mouhieddine
  The New England Journal of Medicine. 2025-08-21
• 3 citations
  International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.
  Hervé Avet-Loiseau, Faith E Davies, Mehmet K Samur, Jill Corre, Mattia D'Agostino
  Journal of Clinical Oncology. 2025-08-20

Abstracts/Posters

• A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma
  Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
  Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)
  Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
  Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
  Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
  Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
  Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
  Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance
  Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes
  Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
  Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
  Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
  Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all